Anthony Chang, MD, MBA, MPH, MS
Dr. Chang attended Johns Hopkins University for his B.A. in molecular biology prior to entering Georgetown University School of Medicine for his M.D. He then completed his pediatric residency at Children’s Hospital National Medical Center and his pediatric cardiology fellowship at Children’s Hospital of Philadelphia.
He accepted a position as attending cardiologist in the cardiovascular intensive care unit of Boston Children’s Hospital and as assistant professor at Harvard Medical School. He has been the medical director of several pediatric cardiac intensive care programs (including Children’s Hospital of Los Angeles, Miami Children’s Hospital, and Texas Children’s Hospital) and is currently the Chief Intelligence and Innovation Officer and Medical Director of the Heart Failure Program at Children’s Hospital of Orange County. He has also been named a Physician of Excellence by the Orange County Medical Association.
He is known for several innovations in pediatric cardiac care, including introducing the cardiac drug milrinone and co-designing (with Dr. Michael DeBakey) an axial-type ventricular assist device in children. He has helped to build a successful cardiology practice as a company and was able to complete a deal on Wall Street. He is a committee member of the National Institute of Health pediatric grant review committee. He is also the editor of several textbooks in pediatric cardiology, including Pediatric Cardiac Intensive Care, Heart Failure in Children and Young Adults, and Pediatric Cardiology Board Review.
He is the founder of the Pediatric Cardiac Intensive Care Society (PCICS) that launched the multi-disciplinary focus on cardiac intensive care for children. He is also the founder of the Asia-Pacific Pediatric Cardiac Society (APPCS), which united pediatric cardiologists and cardiac surgeons from 24 Asian countries and launched a biennial meeting in Asia that now draws over 1,000 attendees.
He has completed a Masters in Business Administration (MBA) in Health Care Administration at the University of Miami School of Business and graduated with the McCaw Award of Academic Excellence. He also completed a Masters in Public Health (MPH) in Health Care Policy at the Jonathan Fielding School of Public Health of the University of California, Los Angeles and graduated with the Dean’s Award for Academic Excellence. He recently completed his Masters of Science (MS) in Data Science with a sub-specialization in artificial intelligence from Stanford School of Medicine. He is also a computer scientist-in-residence at Chapman University.
He is the founder and medical director of the nascent Medical Intelligence and Innovation Institute (MI3) that is supported by the Sharon Disney Lund Foundation. The institute is dedicated to implement data science and artificial intelligence in medicine and is the first institute of its kind in a hospital. The new institute is concomitantly dedicated to facilitate innovation in children and health care all over the world. He is the organizing chair for the biennial Pediatrics2040: Emerging Trends and Future Innovations meeting as well as the founder of the Medical Intelligence and Innovation Summer Internship Program, which mentors close to 100 young physicians-to-be every summer. He has organized a pediatric innovation leadership group and has started the international Society for Pediatric Innovation (iSPI).
He intends to build a clinician-computer scientist interface to enhance all aspects of data science and artificial intelligence in health and medicine. He currently lectures widely on big data and artificial intelligence in medicine (he has been called “Dr. A.I.” and has given a TEDx talk and on the faculty of Singularity University) (). He has also published review papers on big data and predictive analytics as well as machine learning and artificial intelligence in medicine ()(). He is currently organizing a book project and an international meeting, Medical Intelligence: Big Data, Predictive Analytics, Cognitive Computing, Machine Learning and Artificial Intelligence in Medicine. He is also the co-founder and CEO of a startup company (CardioGenomic Intelligence, LLC) that focuses on artificial intelligence applications such as deep learning in clinical cardiology and genomic medicine.